X

Trial Profile

A phase I trial of ADS-4101 for the treatment of partial onset epileptic seizures in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lacosamide (Primary) ; Lacosamide
Indications Epilepsy
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

27 Apr 2018 Results of two phase 1 studies (CTP: 278641 and CTP:285253) assessing pharmacokinetic evaluations of ADS-4101 (Lacosamide) Modified Release Capsules versus Lacosamide immediate release presented at the 70th Annual Meeting of the American Academy of Neurology
05 Dec 2017 Results assessing safety and efficacy presented at the 71st Annual Meeting of the American Epilepsy Society
02 Nov 2017 According to an Adamas Pharmaceuticals media release, data will be presented at the American Epilepsy Society Annual Meeting in December 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com